v3.26.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - Veraxa Biotech A G [Member] - CHF (SFr)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Entity Information [Line Items]    
Net loss SFr (66,613,990) SFr (28,132,971)
Depreciation and amortization 1,972,554 1,876,482
Share-based compensation expense 52,663,301 18,328,192
Non cash lease expense 181,893
Interest paid on lease liabilities (24,105)
Change in fair value of contingent liabilities 799,168 474,538
Loss on disposal of assets 17,449 27,599
Unrealized loss(gain) on foreign currency translation (76,700) (732,328)
Other non-cash transactions    
Accounts payable 902,389 (123,032)
Accrued expenses 873,273 907,859
Prepaid expenses and other current assets (31,429) 199,459
Other receivables (957,817) 104,155
Other receivables, related party (37,659) (21,268)
Other assets (70,718)
Deferred taxes (724,354)
Other current liabilities 1,224,416 (629,078)
Net cash provided by operating activities (9,902,331) (7,720,393)
Purchase of property, plant and equipment (437,176) (120,877)
Cash flow used in investing activities (437,176) (120,877)
Proceeds from the issue of equity instruments of the company, net of transaction costs 5,755,498 1,851,685
Proceeds from the issuance of notes payable - related parties 1,000,000
Payment of principal portion of lease liabilities (164,640)
Net cash provided by financing activities 6,590,858 1,851,685
NET CHANGE IN CASH (3,748,649) (5,989,585)
Cash, beginning of period 5,362,638 11,352,223
Cash, end of period 1,613,989 5,362,638
Initial recognition of lease liability and right-of-use asset SFr 440,802 SFr 864,486